Search Results
Oct 26, 2025, 22:56 ET Health Canada Grants Authorization for Leqembi® (lecanemab)
approvals, and sales milestones as well as royalties on global sales. About BioArctic AB BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of
More news about: BioArctic
Oct 26, 2025, 16:56 ET Ribo kriegt von der EMA den Status als Orphan Drug für das siRNA-Therapeutikum RBD1016 gegen Hepatitis-Delta-Virus-Infektion (HDV)
Schweden, 26. Oktober 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. und Ribocure Pharmaceuticals AB (Ribo) haben heute bekannt gegeben, dass die Europäische Arzneimittelagentur (EMA) RBD1016 den Status einer Orphan Drug (ODD) für die Behandlung von
More news about: Ribo Life Science
Oct 26, 2025, 16:53 ET Ribo obtient de l'EMA la désignation de médicament orphelin pour le pARNi thérapeutique RBD1016 contre l'infection par le virus de l'hépatite Delta (VHD)
GÖTEBORG, Suède, 26 octobre 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co. et Ribocure Pharmaceuticals AB (Ribo), annoncent aujourd'hui que l'Agence européenne des médicaments (EMA) a accordé la désignation de médicament orphelin au RBD1016 pour le traitement
More news about: Ribo Life Science
Oct 26, 2025, 16:22 ET ISO-Unterausschuss für Häfen und Terminals hält erste Plenarsitzung im Hauptsitz von ZPMC ab
content:https://www.prnewswire.com/de/pressemitteilungen/iso-unterausschuss-fur-hafen-und-terminals-halt-erste-plenarsitzung-im-hauptsitz-von-zpmc-ab-302594727.html
More news about: ZPMC
Oct 26, 2025, 15:50 ET Cardiovalve schließt die Rekrutierung für die TARGET-Studie zur CE-Zulassung für den Trikuspidalklappenersatz ab
content:https://www.prnewswire.com/news-releases/cardiovalve-schlieWt-die-rekrutierung-fur-die-target-studie-zur-ce-zulassung-fur-den-trikuspidalklappenersatz-ab-302594722.html
More news about: Venus Medtech (Hangzhou) Inc.
Oct 26, 2025, 14:16 ET Das 14. MINA International Smartphone Film Festival war von SmallRig, einem weltweit führenden Anbieter von innovativen Imaging-Lösungen, mitveranstaltet worden.
Entwicklung von Werkzeugen mitzuwirken, herausragende mobile Filme zu fördern und an Originalprojekten zusammenzuarbeiten. Die Initiative zielte darauf ab, den Zugang zu Ausr ü stung, Exposition und kreativen Partnerschaften in mehr als 160 Ländern
More news about: SmallRig
Oct 24, 2025, 17:37 ET Ribo obtiene la designación de fármaco huérfano de la EMA para el siRNA terapéutico RBD1016
Suecia, 24 de octubre de 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. y Ribocure Pharmaceuticals AB (Ribo), anunciaron hoy que la Agencia Europea de Medicamentos (EMA) ha otorgado la Designación de Medicamento Huérfano (ODD) a RBD1016 para el tratamiento
More news about: Ribo Life Science
Oct 24, 2025, 16:01 ET Innocan Pharma to Present at the 2025 ThinkEquity Conference
HERZLIYA, Israel and CALGARY, AB, Oct. 24, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical
More news about: Innocan Pharma Corporation
Oct 24, 2025, 16:01 ET Innocan Pharma to Present at the 2025 ThinkEquity Conference
HERZLIYA, Israel and CALGARY, AB, Oct. 24, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
More news about: Innocan Pharma Corporation
Oct 24, 2025, 12:18 ET 再鼎醫藥公布Zocilurtatug Pelitecan（前稱ZL-1310）最新一期臨床數據， 顯示其成為同類首創用於小細胞肺癌的靶向DLL3 ADC的潛力，並啟動全球三期注冊研究
NY會議標題：全體會議3：抗體藥物偶聯物日期/時間：2025年10月24日，美國東部時間上午9:17– 9:27（演講部分），9:27 – 9:45（圓桌討論部分）地點：Hynes Convention Center, Level 3, Ballroom AB 關於小細胞肺癌和 Zocilurtatug Pelitecan (zoci)
More news about: 再鼎醫藥
Oct 24, 2025, 08:00 ET Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
2 Merola JF, Bleakman AP, Gottlieb AB, et al. The Static Physician's Global Assessment of Genitalia: a clinical outcome measure for the severity of genital psoriasis. J Drugs Dermatol.
More news about: Johnson & Johnson
Oct 24, 2025, 07:29 ET Sobi showcases new data across rare inflammatory conditions at ACR 2025
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-showcases-new-data-across-rare-inflammatory-conditions-at-acr-2025,c4256001 The following files are available for download:
More news about: Swedish Orphan Biovitrum AB
Oct 24, 2025, 05:55 ET Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis
More news about: Ribo Life Science
Oct 24, 2025, 05:43 ET Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis
More news about: Ribo Life Science
Oct 24, 2025, 04:10 ET 瑞博生物治療丁型肝炎病毒感染的小核酸藥物RBD1016獲EMA孤兒藥資格認定
北京和瑞典哥德堡 2025年10月24日 /美通社/ -- 蘇州瑞博生物技術股份有限公司（「瑞博生物」）及其子公司Ribocure Pharmaceuticals AB （「Ribocure」）共同宣佈歐洲藥品管理局（EMA）授予其小干擾RNA（siRNA）候選藥物RBD1016孤兒藥資格認定（Orphan Drug Designation, ODD），用於治療丁型肝炎病毒（HDV）的感染。
More news about: 瑞博生物
Oct 24, 2025, 03:30 ET Loomis will publish Interim report on October 31, 2025
STOCKHOLM, Oct. 24, 2025 /PRNewswire/ -- Loomis AB will publish the Interim report for January-September 2025 on October 31, 2025 at 7:30 a.m. (CET). Agenda
More news about: Loomis AB
Oct 24, 2025, 02:37 ET Duni Group: Interim Report January 1 - September 30, 2025
[email protected] Duni AB (publ) Box 237201 22 MalmöTelefon: 040-10 62 00
More news about: Duni Group
Oct 24, 2025, 02:14 ET Hexagon Interim Report 1 January - 30 September 2025
82 66 390, [email protected] This is information that Hexagon AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact
More news about: Hexagon
Oct 24, 2025, 02:01 ET Duni Group's Board of Directors Decides on Updated Group Targets from 2026
[email protected] Duni AB (publ) Box 237201 22 MalmöTelefon: 040-10 62 00
More news about: Duni Group
Oct 24, 2025, 01:55 ET Munters Group AB: Strong performance driven by growth in key industries
[email protected], Phone: +46 (0)702 067 786 This information is information that Munters Group AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact
More news about: Munters Group AB
Oct 24, 2025, 01:48 ET Saab Q3 2025 results: Delivering sustained growth
the domestic defence capability of several nations. The information is such that Saab AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact
More news about: Saab
Oct 24, 2025, 01:33 ET Sivers Semiconductors AB (publ), Publishes Interim Report Q3, July - September 2025
Sivers Semiconductors AB (STO: SIVE), a global leader in photonics and wireless technologies, today announced another solid quarter with Q3 2025
More news about: Sivers Semiconductors
Oct 23, 2025, 18:26 ET CGTN AMERICA & CCTV UN: Globaler Dialog zu Innovation, Offenheit sowie gemeinsamer Entwicklung
zum weltweiten Wachstum beigetragen, während es gleichzeitig die grüne Entwicklung, Innovation und Offenheit vorantrieb. Die Diskussion zielt darauf ab, neue Erkenntnisse darüber zu gewinnen, wie diese Errungenschaften und die sich abzeichnenden politischen Richtungen einen integrativen und nachhaltigen
More news about: MediaLinks TV LLC
Oct 23, 2025, 17:31 ET Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight
Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited,
More news about: DelveInsight Business Research, LLP
Oct 23, 2025, 14:06 ET FORUM HR - PEOPLE & CULTURE 2025
www.comunicazioneitaliana.tv. Diese Initiative zielt darauf ab, einen grenzüberschreitenden Dialog über Innovation, Führung und nachhaltige Arbeitskultur zu fördern.
More news about: Comunicazione Italiana